We are live on ! Find out more
EC

Elmind Capital Portfolio holdings

AUM $398M Turnover 23.08%
This Fund
S&P 500
This Quarter Est. Return
+12.77%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$352M
AUM Growth
+$13.4M
Cap. Flow
-$7.13M
Cap. Flow %
-2.03%
Top 10 Hldgs %
68.76%
Holding
36
New
2
Increased
7
Reduced
6
Closed
2
Avg Time Held
0.2 years
Top 10 Avg Time Held
0.2 years
Top 20 Avg Time Held
0.2 years

Top Buys

Rank Stock Value
1
CTMX icon
CytomX Therapeutics
CTMX
+$19.5M
2
DBVT icon
DBV Technologies S.A. American Depositary Shares
DBVT
+$5.54M
3
KALV icon
KalVista Pharmaceuticals
KALV
+$3.55M
4
ALMS icon
Alumis Inc
ALMS
+$3.25M
5
CGEM icon
Cullinan Oncology
CGEM
+$2.83M

Top Sells

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$11.4M
2
DVAX icon
Dynavax Technologies
DVAX
+$10.5M
3
VRDN icon
Viridian Therapeutics
VRDN
+$9.61M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$8.93M
5
WVE icon
Wave Life Sciences
WVE
+$3.52M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
DSGN icon
26
Design Therapeutics
DSGN
$656M
$2.21M 0.63%
207,900
– –
2025 Q4
1 quarter
APLS icon
27
DELISTED
Apellis Pharmaceuticals
APLS
$2.01M 0.57%
50,000
– –
2025 Q4
1 quarter
ALEC icon
28
Alector
ALEC
$213M
$1.94M 0.55%
900,000
– –
2025 Q4
1 quarter
IMCR icon
29
Immunocore
IMCR
$1.52B
$1.76M 0.5%
58,248
– –
2025 Q4
1 quarter
AMLX icon
30
Amylyx Pharmaceuticals
AMLX
$3.47B
$1.56M 0.44%
112,000
– –
2025 Q4
1 quarter
ENGN icon
31
enGene Therapeutics
ENGN
$115M
$1.43M 0.41%
210,000
– –
2025 Q4
1 quarter
WVE icon
32
Wave Life Sciences
WVE
$629M
$1.29M 0.37%
177,846
-270,000
-60% -$3.52M
2025 Q4
1 quarter
SUPN icon
33
Supernus Pharmaceuticals
SUPN
$2.3B
$1.03M 0.29%
20,000
– –
2025 Q4
1 quarter
EWTX icon
34
Edgewise Therapeutics
EWTX
$4.15B
$315K 0.09%
10,000
-20,000
-67% -$577K
2025 Q4
1 quarter
DVAX icon
35
DELISTED
Dynavax Technologies
DVAX
– –
-679,900
Closed -$10.5M –
LQDA icon
36
Liquidia Corp
LQDA
$3.11B
– –
-90,000
Closed -$3.1M –
1
2

Similar funds

FFS
Fischer Financial Services Harrisburg, Pennsylvania $398M AUM 22.91% 1-Year Est. Return
SFS
Stiles Financial Services Edina, Minnesota $398M AUM 55.89% 1-Year Est. Return
SIC
Shoker Investment Counsel Oxford, Ohio $398M AUM 39.01% 1-Year Est. Return
SIAS
Summit Investment Advisory Services Roseville, Minnesota $398M AUM 21.26% 1-Year Est. Return
HVP
Hudson Value Partners Palm Beach, Florida $399M AUM 48.26% 1-Year Est. Return
AC
Alfreton Capital Radlett, Hertfordshire, United Kingdom $399M AUM 20.53% 1-Year Est. Return
W
WorthPointe La Jolla, California $399M AUM 22.49% 1-Year Est. Return
CL
COWA LLC Tulsa, Oklahoma $399M AUM 25.74% 1-Year Est. Return

Elmind Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Elmind Capital held 36 positions worth $352M, up 3.9% from $339M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Elmind Capital's Q1 2026 filing shows 2 new, 7 increased, 6 reduced and 2 closed positions. Its largest new stake was DBV Technologies S.A. American Depositary Shares: 265,000 shares worth $5.54M. The largest sale was CG Oncology, an estimated $11.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Elmind Capital's largest Q1 2026 buy was DBV Technologies S.A. American Depositary Shares: 265,000 shares worth $5.54M.
  • Elmind Capital added most to CytomX Therapeutics in Q1 2026, an estimated $19.5M increase.
  • Elmind Capital's biggest Q1 2026 reduction was CG Oncology, cutting an estimated $11.4M.
  • Elmind Capital fully exited Dynavax Technologies in Q1 2026, selling an estimated $10.5M.
  • Elmind Capital's ten largest holdings make up 69% of its $352M portfolio in Q1 2026.
  • Elmind Capital opened 2 new positions and closed 2 in Q1 2026.
  • Elmind Capital's portfolio value rose 3.9% quarter-over-quarter to $352M.

Based on Elmind Capital's 13F filing for Q1 2026, filed 15 May 2026.